Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.032x

Based on the latest financial reports, Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) has a cash flow conversion efficiency ratio of 0.032x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥88.11 Million ≈ $12.89 Million USD) by net assets (CN¥2.73 Billion ≈ $399.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (300357) total market value for the company's overall valuation and market capitalisation.

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2009–2024)

This chart illustrates how Zhejiang Wolwo Bio-Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Zhejiang Wolwo Bio-Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore cash flow quality index of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
JHSF Participações S.A.
SA:JHSF3
-0.031x
Ipsos SA
PA:IPS
0.063x
Siloam International Hospitals
JK:SILO
0.027x
IReader Technology Co Ltd
SHG:603533
-0.031x
Nomad Foods Ltd
NYSE:NOMD
0.011x
Pharma Mar S.A.
MC:PHM
0.133x
Neinor Homes SLU
MC:HOME
0.068x
Bonesupport Holding AB
ST:BONEX
0.085x

Annual Cash Flow Conversion Efficiency for Zhejiang Wolwo Bio-Pharmaceutical Co Ltd (2009–2024)

The table below shows the annual cash flow conversion efficiency of Zhejiang Wolwo Bio-Pharmaceutical Co Ltd from 2009 to 2024. View 300357 stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CN¥2.46 Billion
≈ $359.80 Million
CN¥262.44 Million
≈ $38.40 Million
0.107x -36.68%
2023-12-31 CN¥2.30 Billion
≈ $337.10 Million
CN¥388.32 Million
≈ $56.82 Million
0.169x -5.16%
2022-12-31 CN¥2.03 Billion
≈ $296.63 Million
CN¥360.28 Million
≈ $52.72 Million
0.178x -11.44%
2021-12-31 CN¥1.80 Billion
≈ $262.90 Million
CN¥360.58 Million
≈ $52.76 Million
0.201x +19.70%
2020-12-31 CN¥1.53 Billion
≈ $223.62 Million
CN¥256.22 Million
≈ $37.49 Million
0.168x -2.68%
2019-12-31 CN¥1.35 Billion
≈ $197.83 Million
CN¥232.93 Million
≈ $34.08 Million
0.172x -16.93%
2018-12-31 CN¥995.42 Million
≈ $145.66 Million
CN¥206.45 Million
≈ $30.21 Million
0.207x +4.43%
2017-12-31 CN¥801.26 Million
≈ $117.25 Million
CN¥159.13 Million
≈ $23.29 Million
0.199x +6.05%
2016-12-31 CN¥655.58 Million
≈ $95.93 Million
CN¥122.77 Million
≈ $17.97 Million
0.187x -4.93%
2015-12-31 CN¥582.91 Million
≈ $85.30 Million
CN¥114.82 Million
≈ $16.80 Million
0.197x +20.85%
2014-12-31 CN¥513.55 Million
≈ $75.15 Million
CN¥83.70 Million
≈ $12.25 Million
0.163x -29.58%
2013-12-31 CN¥251.92 Million
≈ $36.86 Million
CN¥58.30 Million
≈ $8.53 Million
0.231x +1.97%
2012-12-31 CN¥181.38 Million
≈ $26.54 Million
CN¥41.17 Million
≈ $6.02 Million
0.227x +51.24%
2011-12-31 CN¥127.61 Million
≈ $18.67 Million
CN¥19.15 Million
≈ $2.80 Million
0.150x -6.64%
2010-12-31 CN¥90.44 Million
≈ $13.23 Million
CN¥14.54 Million
≈ $2.13 Million
0.161x +42.42%
2009-12-31 CN¥111.89 Million
≈ $16.37 Million
CN¥12.63 Million
≈ $1.85 Million
0.113x --

About Zhejiang Wolwo Bio-Pharmaceutical Co Ltd

SHE:300357 China Drug Manufacturers - General
Market Cap
$1.49 Billion
CN¥10.18 Billion CNY
Market Cap Rank
#7300 Global
#1569 in China
Share Price
CN¥19.45
Change (1 day)
+1.04%
52-Week Range
CN¥18.92 - CN¥35.30
All Time High
CN¥5101.55
About

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceutical products for the diagnosis and treatment of allergic diseases in China and internationally. The company offers Changdi, a dust mine drops; Changhao, an artemisia annua pollen allergen sublingual drops; and Changdian, a dust mite skin prick diagnost… Read more